OnCo
peoplePerson

Everett E. Vokes

Head and neck cancer leader who established organ-preserving chemoradiation and led ASCO in 2021-22.

Medical oncologist whose trials of induction chemotherapy and chemoradiotherapy shaped head and neck cancer treatment. Chair of medicine at the University of Chicago and ASCO president for 2021-2022.

Role
ASCO President 2021-2022; Chair of Medicine, University of Chicago
Specialisms
Head and neck cancerLung cancerChemoradiation

Papers

2top
TitleJournalYear
Head and neck cancerNew England Journal of Medicine1993
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancerJournal of Clinical Oncology2003

Key papers

1top
rctNew England Journal of Medicine 2022changed practice
CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery

Patients with operable stage II-III lung cancer without EGFR or ALK alterations should have chemo-immunotherapy discussed before surgery rather than only afterwards. Three pre-operative cycles do not compromise the operation and improve cure rates. Whether to continue immunotherapy after surgery, as the perioperative trials do, and whether patients with pCR need any further treatment, remain open questions.

Connected

7top

cancers

2
Head and neck squamous cell carcinomaNon-small-cell lung cancer

technologies

1
IMRT / IGRT (modern external beam)

institutions

2
American Society of Clinical Oncology (ASCO)University of Chicago Medicine Comprehensive Cancer Center

trials

1
RTOG 0129 (HPV analysis)

key papers

1
CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery